Drug Profile
TF 0068
Alternative Names: TF-0068Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Techfields Pharma
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 13 Sep 2023 TF 0068 is still in preclinical phase for Parkinson's disease in USA (Techfields Pharma pipeline; September 2023)
- 29 Jul 2016 Preclinical trials in Parkinson's disease in USA (unspecified route)